DJIA 17,959.44 154.64 0.87%
NASDAQ 4,781.42 16.04 0.34%
S&P 500 2,078.54 7.89 0.38%
market minute promo

GlaxoSmithKline (NYSE: GSK)



company name or ticker
Company Photos
(Click to zoom)

3 Drugmakers Facing a Pivotal 2015

Isis Pharmaceuticals, PTC Therapeutics, and GW Pharmaceuticals all expect 2015 to be a pivotal year in their drive toward becoming commercially viable entities. Should investors jump in before the catalysts spark?

Overvalued Bonds Or Would You Buy Stocks With A PE Of 100?

The Most Disappointing Clinical Failures in 2014

Three Motley Fool contributors tell us what they think were the biggest drug trial failures this year.

Exciting News: A Game-Changing Shingles Vaccine Could Be On Its Way

GlaxoSmithKline plc has reported impressive late stage trial results for its shingles vaccine.

Tax-Loss Selling: 1 Stock We'd Be Glad to Sell Right Now

If you own any of these, it might be a good time to cut your losses and move on.

Agenus Jumps on Positive Data from Shingles Candidate - Analyst Blog

The Early Retiree Portfolio For 2015

Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More

Strength Seen in Agenus (AGEN): Stock Soars 17.2% - Tale of the Tape

GlaxoSmithKline (GSK) Stock Rises Today on Positive Experimental Shingles Vaccine Trial Results

See More Articles...